Skip to main content
. 2011 May 29;5:177–184. doi: 10.4137/CMO.S6252

Table 3.

Results of AVAiL trial.

OS (months) PFS (months) Response rate (%)
Gemcitabine/CDDP/bevacizumab (7.5 mg/kg) HR (95% CI) 13.6 6.7 34.1
0.92 (0.77–1.10) 0.75 (0.62–0.91)

Gemcitabine/CDDP/bevacizumab (15 mg/kg) HR (95% CI) 13.4 6.5 30.4
1.02 (0.85–1.22) 0.82 (0.68–0.98)

Gemcitabine/CDDP 13.1 6.1 20.1